Related Experiment Video
Updated: Apr 23, 2026
An Improved Method for Rapid Intubation of the Trachea in Mice
Published on: February 22, 2016
The use of mitomycin C in pediatric airway surgery: does it work?
1Children's Hospital at Montefiore, Montefiore Medical Center, Bronx, New York, New York, USA.
Purpose Of Review:
To describe the efficacy of mitomycin C in combating airway stenosis.
Recent Findings:
Recent publications discussing mitomycin C utility have not altered the mixed results previously established by prospective trials.
Summary:
Mitomycin C has been used for the past 16 years to inhibit pediatric airway fibroblast proliferation. Its benefit remains more hypothetical than proven and its future role remains uncertain.
Insights
Mitomycin C shows mixed results for treating airway stenosis, with its benefit in inhibiting pediatric airway fibroblast proliferation remaining unproven after 16 years of use.
Area of Science:
- Pulmonology
- Pharmacology
- Cell Biology
Background:
- Airway stenosis is a significant clinical challenge.
- Fibroblast proliferation contributes to airway narrowing.
- Mitomycin C is an antifibrotic agent.
Purpose of the Study:
- To evaluate the efficacy of mitomycin C in managing airway stenosis.
- To review current evidence on mitomycin C's role in airway conditions.
Main Methods:
- Literature review of recent publications.
- Analysis of prospective trials and clinical data.
- Assessment of mitomycin C's impact on fibroblast proliferation.
Main Results:
- Recent studies have not resolved the mixed outcomes previously reported.
- Evidence supporting mitomycin C's efficacy remains inconclusive.
- Prospective trials have yielded inconsistent results.
Conclusions:
- Mitomycin C has been utilized for 16 years to inhibit pediatric airway fibroblast proliferation.
- The clinical benefit of mitomycin C in airway stenosis is largely hypothetical.
- The future application of mitomycin C in this context remains uncertain.
